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Abstract
Chikungunya virus is an emerging arbovirus that is widespread in tropical regions and is spreading quickly to
temperate climates with recent epidemics in Africa and Asia and documented outbreaks in Europe and the
Americas. It is having an increasingly major impact on humankind, with potentially life-threatening and
debilitating arthritis. There is no treatment available, and only in the past 24 months have lead compounds for
development as potential therapeutics been reported. This Perspective discusses the chikungunya virus as a
significant, new emerging topic for medicinal chemistry, highlighting the key viral target proteins and their
molecular functions that can be used in drug design, as well as the most important ongoing developments for
anti-chikungunya virus research. It represents a complete picture of the current medicinal chemistry of
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Abstract: Chikungunya virus is an emerging arbovirus that is widespread in tropical regions 
and is spreading quickly to temperate climates with recent epidemics in Africa and Asia, and 
documented outbreaks in Europe and the Americas. It is having an increasingly major impact on 
humankind, with potentially life-threatening and debilitating arthritis. There is no treatment 
available, and only in the last 24 months have lead compounds for development as potential 
therapeutics been reported. This perspective discusses the chikungunya virus as a significant, 
new emerging topic for medicinal chemistry, highlighting the key viral target proteins and their 
molecular functions that can be used in drug design, as well as the most important ongoing 
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developments for anti-chikungunya virus research. It represents a complete picture of the current 
medicinal chemistry of chikungunya, supporting the development of chemotherapeutics through 
drug discovery and design targeting this virus. 
Key words: alphaviruses; arboviruses; chikungunya virus (CHIKV); chikungunya fever 
(CHIKF); non-structural proteins; envelope proteins; drug discovery  
I. INTRODUCTION 
I.1. Classification, History and Clinical Features. Chikungunya virus (CHIKV) is an 
emerging arthrogenic arbovirus that belongs to the alphavirus genus, family Togaviridae. It has 
been responsible for major outbreaks of devastating human arthritis disease during the past five 
years.1 Chikungunya fever caused by the virus was first described in 1952,2 after an outbreak on 
the Makonde Plateau (named after an ethnic group from East Africa), along the border between 
Tanganyika and Mozambique. During this period, a high proportion of residents of all ages were 
affected by a distinctive disease with a sharp onset of crippling joint pains, severe fever, and a 
conspicuous rash.2 The elders of the Makonde tribes could not remember any previous, similar 
epidemics with these symptoms, suggesting that this was a new illness. The word 
‘‘Chikungunya’’ translates to ‘‘that which bends up’’ relating to the stooped posture developed 
as a result of rheumatologic inflammation.3 Subsequently, only minor outbreaks occurred 
periodically in Africa, however major epidemics were reported in the 1960s and 70s in India and 
Southeast Asia.4 After the 1973 outbreak in India, only sporadic activities were detected for the 
next 30 years, with no major recurrence until a large outbreak in Kenya in 2004.5 This initiated a 
spreading epidemic that reached numerous islands of the Indian Ocean, India, and parts of 
Southeast Asia, and was further detected in 18 countries throughout Asia, Europe, and North 
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America via imported infectious carriers. Over the course of five years, an estimated more than 
2 million cases occurred, with outbreaks in several countries where the virus had not been 
previously documented.6 The first CHIKV hit in Europe occurred in Italy in 2007.7,8  
Nearly 40 countries have detected chikungunya virus infected cases thus far (Figure 1). 
The US National Institute of Allergy and Infectious Diseases (NIAID) in 2008 listed CHIKV as 
a category C priority pathogen: this category includes pathogens that could be engineered for 
mass dissemination in the future, or due to their high morbidity and mortality rates and those 
with major health impacts.9, 10 Recent epidemics were reported in India (1.4 to 6.5 million cases 
in 2006-2007), and 3,000 - 42,000 cases were detected in 2009 in Malaysia and Thailand.11,12 
The CHIKV mortality rate has been estimated to be 1:1000 and most of the deaths occur in 





Figure 1. Worldwide distribution of the Chikungunya virus.10 Reprinted by permission from 
Macmillan Publishers Ltd: Nature Reviews Microbiology, (Vol 8), copyright (2010). 
CHIKV can be transmitted through an urban cycle, man to mosquito to man, or a 
sylvatic cycle, animal to mosquito to man.13 The virus is transmitted to humans by mosquitoes 
of the Aedes genus (Aedes furcifer in Africa and Aedes aegypti in Asia), similar to the dengue 
fever causing virus. However, the Ae. albopictus mosquito was extensively implicated in 
CHIKV transmission during the 2005-2006 outbreak on Reunion island.10  
The switch of the CHIKV vector from Ae. aegypti to Ae. albopictus arose from an 
insufficient number of Ae. aegypti for its transmission.14 A mutation in the E1 envelope protein, 
A226V, increased the CHIKV fitness in Ae. albopictus and improved the transmissibility of the 
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virus through Ae. albopictus to vertebrate species.15 Ae. albopictus has spread to Madagascar, 
the Indian Ocean nations, Africa, Southern Europe and the USA.16, 17 Virus transmission has 
been also reported as a result of maternal-foetal transmission in recent epidemics.18 
Chikungunya fever (CHIKF): The symptoms of CHIKF infection generally start 4–7 days after 
the mosquito bite. Infection presents in two phases, the first being acute, while the second stage 
is persistent (chronic), causing disabling polyarthritis.19 Acute infection lasts 1–10 days and is 
characterized by a painful polyarthralgia, high fever, asthenia (weakness), headache, vomiting, 
rash, and myalgia (muscle pain). Rash is the least reliable symptom, presenting in as few as 19% 
of patients. When a rash is present, it is typically maculopapular in nature, but recent studies 
have also noted vesiculobullous lesions with desquamation.20 The persistent chronic CHIKF 
phase is characterized by polyarthralgia (aches in the joints, joint pains) that can last from weeks 
to years beyond the acute stage.21 Eighteen months after disease onset, 40% of patients are found 
to still have anti-CHIKV immunoglobulin M (IgM).22  
CHIKV attacks fibroblasts, explaining the involvement of muscles, joints, and skin 
connective tissues. The high number of nerve endings within the joints and muscle tissues 
explains the pain associated with CHIKF. Neurological manifestations have also been described 
during the most recent epidemics in India, including disorders such as encephalitis, peripheral 
neuropathy, myelopathy, myeloneuropathy and myopathy.23 Moreover, some cases with multi-
organ failure have also been noted.24  Eye infection (Chikungunya neuroretinitis) has also been 
reported where patients suffered from a sudden, painless diminution of vision in both eyes.25,26 
CHIKV can also infect the cornea and be transmitted via the ocular route.27 
I.2. Virology of the CHIKV. The CHIKV genome (Figure 2) is a positive sense, single 
stranded RNA genome of about 11.8 Kb in size. It consists of two open reading frames 
(ORFs),28 one in the 5` end encoding the non-structural protein precursors: 
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 nsP1: involved in viral mRNA capping via its guanine-7-methyltransferase and 
guanylyltransferase enzymatic activities,  
 nsP2: acts as protease and helicase,  
 nsP3: part of the replicase unit and an accessory protein involved in RNA synthesis, 
 nsP4: RNA-dependent-RNA polymerase,  
The nsP123 precursor and nsP4 function as part of a complex for viral negative-strand RNA 
synthesis. The 3` end ORF encodes the structural proteins, the capsid (C), envelope 
glycoproteins E1 and E2 and two small cleavage products (E3, 6K). The untranslated junction 
region (J) (Figure 2) contains its internal promoter, a conserved sequence of 21 nucleotides, for 
transcription of the sub-genomic mRNA in other alphaviruses (sindbis virus, for more details 
see ref 29).29  
 
Figure 2. Schematic representation for The CHIKV genome showing the RNA sequence ORFs. 
 
The CHIKV surface consists of 80 trimeric spikes composed of heterodimers of the envelope 
glycoproteins (E1 and E2) in the lipid bilayer. Similar to other members of the alphaviruses, the 
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CHIKV starts its life cycle (Figure 3) by entering the target cells by pH dependent endocytosis 
in clathrin coated vesicles via receptor mediated interaction,30 but the exact mechanism by 
which it does so remains unclear. CHIKV has been shown to replicate in a large number of cell 
types including epithelial, endothelial and fibroblast cells as well as monocyte derived 
macrophages.30 A recent study identified prohibitin (PHB) as a microglial cell expressed 
CHIKV binding protein.31 PHB is an evolutionarily conserved and ubiquitous protein that 
consists of two highly homologous proteins of different molecular weights. PHB1 has a mass of 
approximately 30 kDa while PHB2 is approximately 37 kDa. The two proteins oligomerize, and 
hetero-oligomerization is essential for protein stability.32 PHB has been shown to be present in 
multiple cell compartments including the mitochondria, cytoplasm and nucleus in addition to its 
expression on the cell surface.33 PHB1 was confirmed as a CHIKV E2 binding protein, but not 
PHB2.31 PHB1 was found to be involved in the internalization process either on its own or as 
part of a complex, further suggesting that a PHB-virus interaction may be mediated by the 
specific PHB molecule that interacts with the virus. Experimental down-regulation of PHB1 
significantly reduced the level of infection in tested cell lines. However, the authors believe that 




Figure 3. Schematic representation of the Chikungunya virus life cycle. 
 
After entering the cell, the endosome acidic environment triggers conformational 
changes with the viral envelope proteins (E1 and E2 complex) reorganizing, leading to 
dissociation of the E2-E1 heterodimers, and formation of E1 homotrimers. E1 trimerizes and 
inserts into the target membrane with the hydrophobic fusion peptide (fusion loop) and refolds 
to form a hairpin-like structure. Exposure of the E1 fusion peptide mediates virus host cell 
membrane fusion, releasing the nucleocapsid into the cytoplasm.34,35 This process depends on 
low pH and cholesterol, which is also required for budding during alphavirus infection.36,37 
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Two non-structural proteins precursors are translated from the viral mRNA, and are then cleaved 
generating nsP1, 2, 3 and 4. During translation, nsP123 binds to free nsP4 and with some cell 
proteins, forming the replication complex,38,39 which synthesizes a full-length negative-strand 
RNA intermediate required for replication. When the nsP123 concentration increases, it is 
cleaved into nsP1, nsP2, nsP3 and nsP4 which forms, along with host cell proteins, the positive 
strand replicase, producing the 26S sub-genomic positive strand RNAs and genomic (49S) 
RNAs.39 Promoters present in the negative strand initiate the transcription of 26S sub-genomic 
positive stranded RNA which encodes the structural proteins precursors. The latter is cleaved by 
a serine protease to yield the capsid (C) which remains in the cytoplasm (Figure 3), pE2, 6K and 
E1.40 The C protein might be responsible for such autoproteolytic activity as it has a number of 
conserved sequences which have similar activity, and are common in other alphaviruses.41  
pE2 and E1 are translated in the endoplasmic reticulum (Figure 3) and processed in the 
Golgi, and are then moved to the plasma membrane, where pE2 is cleaved by furin-like protease 
activity in the host cell into E2 and E3.42 The assembly of virions begins in the cytoplasm of the 
cell, where the formation of the nucleocapsid with 120 dimers of the C protein starts to occur.43 
The assembled particle buds at the cell membrane as spherical particles of 65 to 70 nm in 
diameter, composed of genomic RNA molecules and the capsid proteins and enveloped in a 
host-derived lipid membrane.  
I.3. The Development of CHIKV Vaccine. There is an urgent need to control the spreading of 
CHIKV, however, there is little understanding of the interaction between the chronic CHIKV 
infection and the immune system in defending the body against any subsequent reinfection.10 
The immune responses are strongly accepted to induce autoimmunity, by cross reactivity 
between viral and host antigens. The B cells and T cells might respond to CHIKV and this may 
contribute to the long-term joint disease experienced by many convalescent patients.44  
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Thus far, there is no licensed CHIKV vaccine. Some vaccine preparations that involved 
either formalin inactivation or Tween-ether extracts of virus45 showed high immune responses 
without any adverse effects. In 2000, the US Army carried out a Phase II clinical trial examining 
a live attenuated CHIKV vaccine.46,47,48 The vaccine was formulated from a human MRC-5 cell 
line as a lyophilized supernatant. In this study, subjects that received the vaccine developed 
neutralizing antibodies, and fewer subjects showed mild to moderate joint pain.48 
In 2009, one study reported a vero cell adapted formalin inactivated prototype vaccine 
with alhydrogel as adjuvant that was prepared using an Indian CHIKV strain implicated in the 
2006 epidemic. The humoral immune response was characterized by high titer antibodies that 
have been confirmed through microcytotoxicity assays and in vivo neutralization tests. 
Therefore, this could be a promising, safe and effective vaccine eliciting a long lasting 
protective immune response.49  
A live CHIKV vaccine was developed in 2011 that elicits a protective immune response 
with no detectable disease in mice. It is also unable to infect mosquito vectors, which is an 
important safety feature for a live virus vaccine that could be used in non endemic areas to 
immunize travellers or laboratory personnel. However, this vaccine candidate is still under 
evaluation in nonhuman primates.50 Other promising CHIKV vaccine candidates that depend on 
virus-like particles are in early stages of preclinical development.51,52  A successful virus-like 
particle vaccine based on viral structural proteins was tested on nonhuman primates and was 
found to produce neutralizing antibodies that protect against viremia after high-dose challenge. 
When these antibodies were transferred into an immunodeficient host (a mice), the host was 
protected indicating a passive immunity.53  
With the ongoing vaccine development research against the CHIKV, the world remains 
under the threat of rapidly spreading CHIKV infections, and this emphasizes the importance of 
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developing chemotherapeutics targeting the virus for controlling already existing infections in 
devastated areas.  
II. EMERGING NOVEL CHIKV TARGETS 
 As previously mentioned, the CHIKV genome is formed of 2 ORFs, one from the 5` end 
coding for nsP1, nsP2, nsP3 and nsP4. The 3` end ORF encodes the the capsid (C), envelope 
proteins E1, E2, E3 and 6k (Figure 2). These proteins, which mediate essential steps in the 
lifecycle (Figure 3) of the virus,10 could be possible targets for drug design.  
II.1. Non-Structural Proteins 
II.1.1. Non-structural protein 1. Like in other alphaviruses, CHIKV nsP1 is a palmitoylated 
535 amino acid protein. The N-terminal region is a methyltransferase and guanylyltransferase 
involved in capping and methylation of the newly formed viral genomic and subgenomic 
RNAs.54 In early 2013, it was shown that CHIKV nsP1 acts as antagonist for the bone marrow 
stromal antigen 2 (BST-2).55 BST-2 is one of the host cell defence mechanisms, and is induced 
by interferon (INFα). BST-2 expression results in retaining viruses at the surface of the infected 
cells.56 BST-2 was found to co-localize with CHIKV E1 and nsP1, but only nsP1 is able to 
down-regulate BST-2 expression, thereby inhibiting virus tethering on the cell surface.55 This 
activity of the CHIKV nsP1 is similar to that of the HIV-1 Vpu protein56 in that both repress 
BST-2. This discovery will help in developing BST-2 mediated therapeutics targeting the nsP1. 
II.1.2. Non-structural protein 2. The non-structural protein 2 (nsP2) of alphaviruses is a 
multifunctional protein.57,58,59,60 The proteolytic domain has been allocated to its C-terminal 
section which forms a papain like cysteine protease (also known as thiol protease).57,61 The nsP2 
proteolytic activity is critical for virus replication and is responsible for cleavage of the non-
structural polyprotein complex.62,63 
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The proteolytic activity of the CHIKV nsP2 has been demonstrated,64 and the enzymatic 
activities within the N-terminus have been recently investigated. It was found to have RNA 
triphosphatase activity that performs the first of the viral RNA capping reactions. It was also 
found to have a nucleotide triphosphatase (NTPase) activity, fueling the RNA helicase activity 
performed by the C-terminal domain.65 CHIKV-nsP2 also has 5`-triphosphatase (RTPase) 
activity that removes the γ-phosphate from the 5` end of RNA. Both NTPase and RTPase 
activities are completely dependent on Mg2+ ions.65  
Both N and C domains are composed of α-helices and β-strands (Figure 4). The N 
terminus is dominated by α-helices, whereas the C-terminal domain contains helices and strands. 
The central β-sheets are flanked by α-helices. The crystal structure of CHIKV nsP2 protease has 
been solved, and is composed of 324 residues. Being a cysteine protease, the catalytic 
mechanism involves a nucleophilic cysteine thiol in a catalytic dyad.66 Analysis of the CHIKV 
nsP2 crystal structure shows 6 cysteine residues, three in the N-terminus (Cys1013, Cys1057 
and Cys1121) and three in the C-terminus (Cys1233, Cys1274 and Cys1290) as shown in Figure 
4. Since the proteolytic activity is isolated in the C-terminus,64 one of the three cysteine residues 




Figure 4. CHIKV nsP2 crystal structure showing the N- and C-terminal domains, cysteine 
residues shown in yellow balls and stick form (pdb code: 3TRK67, no citation was found for the 
crystal structure). 
 
The first step in the mechanism of cysteine proteases catalysis is usually the 
deprotonation of a thiol  group within the enzyme active site by an adjacent amino acid 
containing a basic side chain, often a histidine residue.68 Among the three cysteine residues in 
the C-terminus (Figure 5), the Cys1274 residue is less likely to be involved in the catalytic 
mechanism as only one His residue (His1314) is nearby, whereas for the other cysteine residues, 
four His residues, His1222, His1228, His1229 and His1236 could be associated in the 




Figure 5. Schematic representation of the CHIKV nsP2 C-Domain showing the positions of the 
cysteine residues (yellow) and histidine residues (green), generated from the crystal structure 
pdb file code: 3TRK. 
 
In 2012, Singh Kh et al. reported the development of a homology model of the CHIKV 
nsP2 protein based on the crystal structure of the nsP2 protein of Venezuelan equine encephalitis 
virus (VEEV),69 in order to locate the active site of the protease. The critical residues in nsP2 
were identified by docking three different peptides to identify the residues responsible for non-
structural protein cleavage of the nsP1-2, nsP2-3 and nsP3-4 peptides. These three peptide 
sequences represent the substrates for the nsP2 proteolytic processing with a remarkable 
preference of nsP3-4>nsP1-2>nsP2-3.70 
The active site was investigated and was found to lie in the C-terminal domain69 (Figure 
5). The key residues Gln1039, Lys1045, Glu1157, Gly1176, His1222, Lys1239, Ser1293, 
Glu1296 and Met1297 were found to interact with the non-structural protein sequence complex 
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to be cleaved, and were considered an individual functional unit. Only two residues are located 
in the N-domain, Gln1039 and Lys1045, with all the other residues located in the C-domain. 
Analogous work by Bassetto et al.71 reported the development of a homology model for the 
nsP2 protease active site within the C-domain. 
The predicted active site by Singh Kh et al.69 and Bassetto et al.71 matches with the 
above mentioned explanation of the positioning of the active site within the C-domain. In 
particular, they found the His1222 residue to be lying within the predicted active site pocket. 
Analysis of the enzyme surface shows that the predicted active site is located in a major surface 
groove as shown in Figure 6, with the major cavity on the enzyme surface more likely to 
accommodate the substrate polyprotein sequence to be cleaved.  
    
Figure 6. Electrostatic potential surface of the CHIKV nsP2 and its active site pocket within the 
C-domain, a) The active enzyme surface front view showing the active site as a transparent red 
sphere surrounding the active site with the Cys1233 and His1222 residues lying within the 
sphere. b) Side view of the enzyme (rotated to the left by 90º about the vertical axis from the 
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view in a) showing the major accessible cavity to the active site with a part of the sphere 
protruding toward the outer surface, generated from the pdb file 3TRK.  
This major enzyme groove (Figure 6b) may act as the enzyme mouth holding the protein 
to be processed. Therefore, targeting the residues identified above,69 as well as the residues 
within the active site, would be applicable strategy to inhibit the enzyme function and 
consequently inhibiting the virus replication. 
Moreover, the alphaviruses nsP2 proteins have been described as virulence factors 
responsible for the transcriptional and translational shutoff in infected host cells and the 
inhibition of interferon (IFN)-mediated antiviral responses contributing to the controlling of 
translational machinery by viral factors.72,73 This controlling comes through interactions with 
cellular RNA binding proteins, including heterogeneous nuclear ribonucleoproteins (hnRNPs), 
ribosomal protein S6 (RpS6), and cellular filament components. Recently reported was the 
believed interaction of 22 cellular components with nsP2 or nsP4, contributing to the CHIKV 
replication, mainly heterogeneous nuclear ribonucleoprotein K (hnRNP-K) and ubiquilin 4 
(UBQLN4). It was also noted that the interaction of nsP2 with the tetratricopeptide repeat 
protein 7B (TTC7B) plays a significant role in the cellular machinery control induced by the 
CHIKV infection.74 
II.1.3. Non-structural protein 3. The function of alphaviruses nsP3 remains unknown, 
although mutations can affect different steps of the viral replication machinery.75 It is 
constructed of two domains, the first being a unique macro domain in the conserved N-terminal 
region. The C-terminal region is less conserved and is phosphorylated in approximately 16 
positions on serines and threonines.76,77 The function of phosphorylation is not understood, but it 
was found that deletion of these phosphorylated residues decreases the level of RNA synthesis.78 
Interestingly, viral pathogenicity of Semliki Forest virus (SFV), another alphavirus, is decreased 
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in absence of that phosphorylation on the nsP3, and the absence of the C terminus alters SFV 
neurovirulence.79 
The N-terminus of nsP3 contains a macro domain (known also as the X domain), which 
binds to ADP-ribose derivatives and RNA, and is able to hydrolyse ADP-ribose-1``- 
phosphate,80,81 a side product of cellular pre-tRNA splicing. Therefore, it is believed to control 
the metabolism of ADP-ribose 1``- phosphate and/or other ADP-ribose derivatives which have 
regulatory functions in the cell. The ADP ribose–binding site within the nsP3 macro domain is 
solvent-exposed and points away from the other domains in the nsP23 polyprotein. Based on 
sequence conservation in alphaviruses, it has been shown that residues just after the nsP3 macro 
domain play a role in positioning of the nsP23 complex cleavage site.82 It can be inferred from 
the crystal structure of the nsP23 precursor protein of the closely related alphaviruses, SINV, 
that the nsP2 is connected to the nsP3 through the macro domain of the nsP3.83 The nsP23 
cleavage site is located in a narrow cleft formed between nsP2 and nsP3 that is inaccessible for 
proteolysis, and all the nsP2 non-cytopathic mutants lie at the interface between nsP2 and 
nsP3.83 The inaccessibility of the nsP23 cleavage site indicates that access is tightly regulated. It 
is believed that the activator segment is located in the amino-terminus of the nsP2 which 
becomes exposed after cleavage from the nsP12 precursor poly protein.84  
In 2010, the crystal structure of the nsP3 macro domain for the CHIKV was solved80 
(Figure 7). It consists of 672 residues and contains six-stranded β sheets with three α helices. 
The intermolecular interactions between the residues in the binding pocket of the enzyme and 





Figure 7. Crystal structure of the CHIKV macro domain with the bound ADP-ribose (yellow 
colour), generated from the pdb file code: 3GPO.  
 
Figure 8. 2D representation of the interaction of ADP-ribose inside the nsP3 macro domain 




As shown in Figure 8, the key binding residues are: Arg144, Asp10, Ile11 Thr111, Gly112, 
Ser110, Tyr114, Val113, Asn24, Asp31 and Val33. The binding complex is formed of 10 H-
bonds and one π-cation interaction.85 The PO4
2− moiety showed the strongest interactions with 
these residues in the enzyme pocket. Also, the ribose (with Thr111) and the diphosphate (with 
Val 33, Ser110, Gly112, Val113, Tyr114) units were found to play major roles in the CHIKV 
nsP3 ADP-ribose complex.85 
Understanding this binding interaction of the ADP-ribose to the macro domain of the CHIKV 
could therefore be a useful element to further assist in drug design and development of inhibitors 
for this virus. Bound inhibitors to the ADP-ribose binding pocket will alter the function of the 
nsP3 either cleaved or in a polyprotein complex, and consequently will alter the function of the 
viral replication machinery.  
Recently, more insights on the molecular function of the nsP3 revealed interesting findings, it 
was reported that the nsP3 of CHKV, as with other alphaviruses, use a conserved proline-rich 
motif to interact with the Src-homology-3 (SH3) domain of amphiphysin-1 and amphiphysin-2 
proteins of the host cell, two related member proteins of the BAR (Bin-Amphiphysin-Rvsp) 
protein superfamily implicated in several cellular functions.86 
More recently,87 the nsP3 has been shown to be the inhibitor of stress granule assembly by 
recruiting G3BP into cytoplasmic foci. The conserved nsP3 SH3 domain-binding motif (the 
proline-rich motif) is essential for both nsP3-G3BP interactions and viral RNA replication. 
G3BP (Ras GTPase-activating protein-binding protein) is an enzyme in human cells and a 
member of the heterogeneous nuclear RNA-binding proteins.88 This protein plays a major role 
during infection and in the assembly of stress granules. Stress granules are membranous 
cytoplasmic focal structures (foci) that immediately aggregate in response to cellular stress. This 
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last action leads to impaired translation of most mRNAs.89 These stress granules may have 
antiviral activity that is inhibited by CHIKV replication by the nsP3 SH3 domain-binding 
motif.87 
II.1.4. Non-structural protein 4. The non-structural protein 4 was identified as the RNA-
dependent-RNA polymerase,29,90 and was recently found to suppress the host cell unfold protein 
response (UPR), also named as the endoplasmic reticulum (ER) stress response.91 The UPR is a 
mechanism that maintains the cellular protein homeostasis and prevents over-loading of 
unfolded protein in the lumen of the ER during normal and diseased cellular conditions. The 
UPR is multi-stepped and involves contributing proteins, including the PKR-like ER kinases 
(PERK).92 During the UPR, PERK is activated by self-dimerization and phosphorylation, which 
then phosphorylates the serine 51 position of the eukaryotic translation initiation factor 2, alpha 
subunit (eIF2α), an essential factor for protein synthesis. Phosphorylated eIF2α inhibits the 
general protein synthesis, and consequently, will inhibit the pathogen protein replication. The 
CHIKV nsP4 was found experimentally to significantly reduce the phosphorylation (serine 51) 
of eIF2α, and thus ensuring the translation of the viral protein.91 This discovery can be exploited 
as possible target for anti-CHIKV intervention. The crystal structure of the CHIKV nsP4 is not 
yet available for the structure based inhibitors discovery, and more efforts should be devoted to 
decipher the mechanism of action for that protein as well as experimental tools to evaluate 
possible potential protein inhibitors.  
II.2. Structural Proteins 
The invasion of susceptible cells by the CHIKV is performed by two viral glycoproteins, E1 and 
E2. Both carry the basic antigenic determinants and form the icosahedral shell of the virion 
particle. E2 and E3 are produced from furin cleavage of the p62 (also known as PE2, see Figure 
21 
 
2) precursor. E2 is responsible for receptor binding whereas E1 mediates the membrane fusion.10 
E3 contains the 64-amino-terminal residues of p62.93 
E1 and p62 peptide are type I membrane proteins and are derived from a structural 
polyprotein precursor. They are translated in the infected cell endoplasmic reticulum, into a 
p62–E1 heterodimer and processed by the Golgi (Figure 3). E3 protects the E2-E1 heterodimer 
from premature fusion with cellular membranes.94 The heterodimers trimerize forming the viral 
spikes. Cleavage of p62 into E3 and E2 during transport to the cell surface prepares the spikes 
for the fusogenic activation to enter the cell. At the plasma membrane, the formed virions bud 
through interactions between E2 and genome-containing viral nucleocapsids in the cytoplasm.95  
In a recent study, the roles of four amino acid residues (G91, V178, A226, and H230) in 
the CHIKV E1 protein were linked to the E1 and cell fusion process.96 The study revealed that 
the highly conserved amino acid residues, G91 and H230, were important for membrane fusion 
functionality. The glycine residue (G91) is critical for the fusion process whereas any mutation 
or substitution in this residue lead to complete loss of E1 fusion ability. The E1 histidine 230 is 
located outside of the fusion sequence, but still critical for the fusion. Other structural proteins 
also affect the E1 fusogenic capacity, e.g. the E2 protein facilitates both E1 folding and regulates 
E1 fusogenic properties in a pH and cholesterol dependent process.96 As an alphavirus family 
member, the hydrophobic fusion peptide of the CHIKV was found to be a trimer of hairpins 
composed of β-sheets in the post fusion state (type II fusion proteins).97,98 Figure 9 shows the 
crystal structure of the CHIKV fusion peptide,99 consisting of 18 amino acid residues, which are 




Figure 9. Hydrophobic surface view of the CHIKV fusion peptide showing the residue G91 in 
red label located at the back side (generated from the crystal structure of the fusion peptide, pdb 
file code: 2RSW99). 
 
The crystal structures of the CHIKV p62-E1 (immature) and the E3-E2-E1 (mature) 
glycoprotein complexes are shown in Figures 10-12. E1 is folded into three domains I, II and III 
(Figure 11) that are rich in β-sheets. E2 is an immunoglobulin β protein, with three domains (A, 
B and C). Domain A is at the centre and domain B is at the membrane upper end whereas 
domain C is towards the viral membrane. The latter binds to domain II of E1 by hydrogen 
bonding due to the hydrophilic contact region between them (Figure 10). The long β – ribbon of 
E2 makes most of the connection with E3 (Figure 12). Furin loop (Figure 10) is the E2E3 
junction in the immature complex, this junction contains a functional proprotein convertase 
motif which is cleaved by the cellular proteases, furin-like proprotein convertases, during the 
maturation (Figure 3) of the glycoproteins.42 Variations within this junction site among the 
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different CHIKV isolates greatly affect the cleavage susceptibility by furin proteases. The amino 
acid His60 (residue 56 in the crystal structure pdb file: 3N40) is the critical residue that 
determines the spectrum of furin and furin-like convertases that process E2E3 glycoprotein 
complexes.100 It can be inferred from the comparison between the immature and the mature 
glycoprotein complexes structures,95 that the short peptide sequence (Pro59, His60, Arg63, 
Glu64, Ser65, Thr66, Lys67 and Asp68) is cleaved form the immature complex after furin 
cleavage. 
 
Figure 10. Crystal structure of the immature envelope glycoprotein complex of Chikungunya 
virus, E1 is formed from domains I, II and III. E2 contains domains A, B and C. Structure 
generated from the pdb file code: 3N4095. E3 stabilizes the E2 β–ribbon connector94 being 
associated with domain A of E2 and domain II of E1, allowing domain B to protect the fusion 
loop. 
 
The U shaped fusion loop of E1 is inserted in a cavity that lies between the E2 domains 
A and B, being stabilized by hydrogen bonds (Figure 13) with E2 histidine side chains.95 At 
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neutral pH, E3 maintains the relative orientation of E2 domains B and A creating a cavity space 
that accommodates the E1 fusion loop. This orientation by E3 protects the virus from premature 
fusion with other cellular membranes.95,101 The fusogenic activity of the E1 fusion peptide is 
therefore highly dependent on pH change. The histidine residues of E2 act as the pH sensor for 
the activation of the fusion protein at lower pH95 due to the increased probability of histidines to 
become positively charged at lower pH values (acidic endosome), based on the fact that the 
imidazole ring of the histidine residue is the only amino acid side chain whose apparent 
dissociation constant from protons (pKa) falls within the physiological range. 
 
 
Figure 11. Crystal structure of E1 glycoprotein formed of 393 residues (residue 402-residue 794 
within the whole complex structure), separated from the complex for visualization, generated 




Figure 12. Crystal structure of E2, E3 glycoprotein complex formed of 401 residues (residue 1-
residue 401 within the whole structural protein complex), separated from the complex for 
visualization. Generated from the pdb file code: 3N4095. 
 
Some important locations (transitional epitopes) were identified in both E1 (domain III) 
and E2 (domain B) of alphaviruses: these locations become accessible upon exposure to heat or 
low pH102,103 as well as upon contact of the virions with the susceptible cells. This contact leads 
to conformational changes related to cell binding,104 with domain B moving out in relation to 
domain A, thus opening the cavity. The fusion loop now becomes free to release,95 without a full 
dissociation of the E2–E1 heterodimer. Other residues in domain B of E2 are believed to be 
associated with cell recognition assuming that a number of sites on the virus surface can interact 





Figure 13. Crystal structure of the CHIKV mature envelope glycoprotein complex. E1 is viewed 
as hydrophobic surface with the critical amino acid residue Gly9199 of the fusion loop labelled in 
black. E2 and E3 are viewed as a solid ribbon, and histidine residues on E2 are viewed as stick 
structures in red surrounding the fusion loop and acting as the pH sensors.95 Generated from the 
pdb file code: 3N4295.  
 
Recently, the possible druggable pockets within the CHIKV envelope proteins have been 
determined (Figure 14), with two found to be critical to the protein functions, mainly the fusion 
process.105 The green pocket (Figure 14) represents a surface cavity that lies between the E1 
domain II and E2 β–ribbon that connects E2 domain A to E2 domain C. It extends downwards 
as a channel between E1 domain II and E2 domain A. The blue pocket (Figure 14) is a narrow 
channel extending just behind the fusion loop and is surrounded by both E2 domains A and B. 
These pockets make contact with residues from E1 and E2 and therefore, ligands for these 
pockets can affect the relative movement of E1 and E2 domains in the pre- and post-fusion 
states. Furthermore, the blue pocket (Figure 14) makes contact with the fusion loop residues, 
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and therefore, designing antagonists for this pocket with would be applicable strategy to block 
the fusion function.105 
 
Figure 14. Possible druggable cavities within the CHIKV envelope proteins illustrated as blue 
and green space-filling pockets. E1 is coloured in violet, E2 is coloured in orange and E3 is 
shown in red. For simplicity, the figure illustrates only a component of the glycoprotein mature 
envelope complex. Generated from the pdb file code: 3N4295.  
 
II.3. Highlights for the CHIKV target enzymes 
With the recent growing knowledge and available structural information about the CHIKV 
genome, drug design of specific inhibitors targeting individual viral proteins has become more 
viable. The most promising targets from a chemical and biological standpoint would be the viral 
protease (nsP2) and the viral envelope proteins. The first protein has a complete crystal structure 
for the N and C domains, with the critical residues for proteolytic activity already investigated. 
This nsP2 protein also functions through the N domain, allowing the possibility of medicinal 
chemistry intervention at both domains on this protein. The challenge is the current lack of 
individual enzyme-based assays to investigate the inhibitory effects of the designed protein 
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antagonists, rather than the whole cell assay protocols. The second promising protein target is 
the viral envelope proteins where specific residues have been identified to be essential for the 
viral fusion process, e.g. the Gly91 and His230 residues. Designing specific inhibitors targeting 
the viral fusion process would be valuable for the inhibition of alphaviruses in general. The viral 
nsP3 also represents a possible drug design target, with the structure of the conserved macro 
domain is already known. However, this target requires further investigation, e.g. the solving of 
the complete protein structure. 
III. DEVELOPMENT OF CHEMOTHERAPEUTICS AGAINST CHIKV: NEW 
MEDICINAL CHEMISTRY LEADS  
There is currently no recognised single antiviral treatment for chikungunya. During the recent 
outbreaks that occurred in the Indian Ocean nations, only treatments for symptoms were 
available, based on non-steroidal anti-inflammatory, non-salicylate analgesics and fluids. Mild 
physical exercise is believed to decrease the joint stiffness, but heavy exercise may increase the 
rheumatic pain. During chronic CHIKV infection, corticosteroids may be used to help decrease 
the inflammation.106 The status of drug discovery for the CHIKV is still in the very early stages 
with no drugs currently in clinical trials. The first mouse model to study the pathophysiology of 
the resulting disease was developed in 2008,107 after which several animal models were 
developed to aid the understanding of the drug-disease interactions that would facilitate the 
development of effective therapy.108 
III.1. Protease inhibitors. Targeting the CHIKV nsP2 protease activity within the C-domain, 
would have an inhibitory effect on the viral replication. Using the developed homology model 
for the nsP2, Singh Kh and co-workers screened a library of compounds in silico and identified 
four compounds (1-4, Figure 15) as potential inhibitors of the nsP2 protease.69 Ideally, binding 
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to this active site will block protein function stopping the replication cycle. However, the 
antiviral activity of these hits has yet to been reported. 
         
            
Figure 15. Structures of the four in silico predicted CHIKV nsP2 inhibitors. 
 
In a similar work, Bassetto et al.71 reported the identification of in silico CHIKV nsP2 
inhibitors through a virtual screening of a large compounds library using the developed 
homology model for the CHIKV nsP2. One of the hits, compound (5, Figure 16) was predicted 
to bind to central portion of the nsP2 protease active site, with its hydrazone group placed in the 
region defined by the catalytic dyad. The in vitro activity of this hit compound was assessed and 
it was found to inhibit the virus at EC50 value of 5 µM with a selectivity index (SI) value of 14, 
through the inhibition of the virus-induced cytopathic effect.71 The central cyclopropyl and the 
hydrazone moieties were found, through a structure activity relationship study, to be important 
for the anti-chikungunya activity. A series of derivatives were also designed based on these 
identified pharmacophores of (5), whereas the cyclopropyl group was replaced with a trans-
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ethenylic moiety (6, Figure 16), maintaining length and geometry of the original linker. The 
antiviral activity was slightly improved with (6) displaying an EC50 value of 3.2 µM and a 
selectivity index (SI) of 32. The binding modes of both compounds (5, 6) inside the nsP2 pocket 
were similar.71 
 
Figure 16. Chemical structures of the CHIKV inhibitors identified from in silico screening, with 
subsequent testing confirming substantial activities. Red circles indicate the only difference in 
the structures responsible for the activity change. 
 
III.2. Furin inhibitors. Infection by alphaviruses can be inhibited in vitro by blocking the 
intracellular furin-mediated cleavage of viral envelope glycoproteins: the E2E3 or p62 
precursors. This blocking was demonstrated by showing the inhibitory effect of an irreversible 
furin-inhibiting peptide, decanoyl-RVKR-chloromethyl ketone (dec-RVKR-cmk, 7, Figure 17) 
on in vitro CHIKV infection.100 This peptide significantly reduced the processing of E3E2 
CHIKV glycoproteins in infected myoblast cultures and led to the formation of immature viral 
particles and impaired viral spreading among cells, but not the replication in cells already 
infected.100  Therefore, the chemical structure of the furin-inhibiting peptide (7) could be a 
starting point for generating novel generations of active peptidomimetics using the ligand-based 




Figure 17. Structures of the CHIKV furin-inhibiting peptide (7). 
 
III.3. Chloroquine and Quinine. The in vitro antiviral activity of chloroquine (8, Figure 18) 
was first reported more than 35 years ago and has been successfully used as an anti-malarial 
drug.109,110 With respect to the alphaviruses, chloroquine was found to be effective in 
vitro,111,112,113 however, recently a mouse model revealed that chloroquine may enhance viral 
replication in vivo leading to aggravation of the disease.114 Regarding the CHIKF, chloroquine 
and chloroquine phosphate have been used in the treatment of chronic chikungunya arthritis,115 
but only for the anti-inflammatory properties of the molecule (used in chronic rheumatologic 
diseases) rather than for any antiviral effect. Some studies suggest that chloroquine might 
interact with the endosome-mediated internalisation process during the infection cycle, stating 
that chloroquine might be classified as an entry inhibitor. Compound 8 entered phase 3 clinical 
trials in France as a therapy for the CHIKV in 2006, however, these studies were terminated in 




Figure 18. The structure and reported anti-CHIKV activities of the quinolines 8 and 9. 
 
In one clinical study, the effect of 8 on CHIKF patients was investigated using another 
placebo treated group of patients, and at the conclusion, there was no statistical difference 
between the chloroquine and the placebo treated groups regarding the mean duration of febrile 
arthralgia or the decrease of viraemia (viral count in plasma).  
Another anti-malarial drug, quinine (9, Figure 18), also inhibits the virus in vitro at a 
concentration less than that of chloroquine (IC50 = 0.1 µg/ml for quinine, 1.1 µg/ml for 
chloroquine). Also, quinine is suggested to affect the nsP1 as mutations in this protein occur 
upon growing the virus in a high concentrations of quinine.106  
Overall, the contradicting results from different studies casts serious doubt as to the 
effectiveness of chloroquine as an effective chemotherapeutic against CHIKV and until 
resolved, it should be treated with caution as a drug lead.106  
 
III.4. Ribavirin and 6-Azauridine. The antiviral ribavirin (10, Figure 19), is well known to 
inhibit in vitro many RNA viruses, by different mechanisms.116 It is being used either alone for 
treatment of infections as Respiratory Syncytial virus, or in combination with alpha-interferon in 
the treatment of hepatitis C virus (HCV) infection. This combination showed a synergistic effect 
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in vitro in the inhibition of CHIKV.117 A combination of alpha-interferon, at a concentration of 
3.9 IU/ml, and ribavirin at a concentration of 18.75 µg/ml, inhibited CHIKV replication by 50%, 
whereas 10 alone without interferon, inhibited CHIKV with EC50 value of 83.3 µg/ml. However, 
there is no evidence supporting the clinical efficacy of 10 on CHIKV, and the combination with 
interferon should be subjected to clinical trials for the treatment of CHIKV infections.106 
Furthermore, the exact mechanism of ribavirin is still unclear as it may change from virus to 
another, however, it is believed that ribavirin can interact with the intracellular viral RNA 
production.  
  
Figure 19. The structure of nucleosides 10 and 11.  
 
The broad-spectrum anti-metabolite, 6-azauridine (11, Figure 19) inhibits both DNA and 
RNA virus replication, and the activity might be through the inhibition of orotidine 
monophosphate decarboxylase, an enzyme involved in the de novo biosynthesis of pyrimidine, 
cytidine and thymidine.118 It showed a significant inhibition of CHIKV at a low concentration 
(0.2 µg/ml) and was more effective against the CHIKV compared to 10.117 Compound 11 is not 
approved for human use and therefore was not included in a combination study with alpha-
interferon. However, the corresponding 6-azauridine triacetate is used for treatment of different 
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diseases without notable adverse effects.119 Therefore, 6-azauridine should be evaluated in vivo 
as CHIKV inhibitor.117 
III.5. Arbidol. The antiviral drug arbidol (12, Figure 20) was originally developed 20 years ago 
at the Russian Research Chemical and Pharmaceutical Institute.120  Since 1990, it has been used 
in Russia for acute respiratory infections including influenza. So far, arbidol shows a wide range 
of activity against many RNA, DNA, enveloped and non-enveloped viruses.121 This broad 
spectrum of activity may be attributed to the different modes of actions including the inhibition 
of virus mediated fusion,122 and blocking of the viral entry into the target cells through inhibition 
of glycoprotein conformational changes that are essential for the fusion process, as in case of 
influenza virus and hepatitis C virus.123,124  
In 2011, 12 and two derived metabolites (Figure 20), 13 (HZ1) and 14 (HZ3), were 
tested in vitro on the chikungunya virus using two cell lines, and under different conditions (pre 
and post-infection treatments). The only active compound was 12 with an IC50 value much lower 
than the toxic concentration (IC50 = 12.2 µM, CC50 > 200 µg/ml).
125 Compounds 13 and 14 were 
assumed to be responsible for the anti-viral properties of arbidol, however in this study, they 
showed only weak effects on CHIKV replication.  
 
Figure 20. The structures of indole-based derivatives 12, 13 and 14.  
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Compound 12 was found to be not viricidal, rather, it blocks the earliest stages of the 
viral replication, virus attachment and/or virus entry as previously reported.121 For CHIKV, it 
works by targeting the cellular membrane (E2 viral envelope protein) which was confirmed by 
the use of an arbidol resistant CHIKV strain (mutation in the E2 protein, G407R).125 However, 
all these studies were performed in vitro and in vivo studies are required to validate the activity 
of arbidol on CHIKV. 
III.6. Mycophenolic acid (MPA). Mycophenolic acid (15, Figure 21) was isolated 
approximately one hundred years ago.126 It acts as an inhibitor for the inosine monophosphate 
dehydrogenase (IMPDH), an enzyme evolved in the de novo biosynthesis of guanine nucleotide. 
It has a good anti-proliferation activity and has been established as an anticancer127 and antiviral 
agent, and as an immunosuppressant.128 
     
Figure 21. The structures of inhibitors of IMPDH, 15 and 16. 
Recently, 15 was shown to inhibit the CHIKV replication by virus induced cell death. 
The IC50 value was 0.2 µM with a selectivity index of 150,
129 and it was found to induce CHIKV 
apoptosis. When the treated CHIKV infected cells were provided with exogenous guanosine 
(GMP), 15 could no more prevent the CHIKV induced cell death, indicating that it worked by 
inhibiting the IMPDH enzyme. It is also suggested that 15 increases the mutation rate during the 
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viral replication.129 Considered as a good lead compound, the in vivo activity of 15 on CHIKV 
requires further investigation as it is known that the compound suffers from a metabolic 
drawback associated with rapid conjugation of the C-7 phenolic hydroxyl group with glucuronic 
acid.130,131  
III.7. Trigocherrin A. Trigocherrin A (16, Figure 21), is a highly oxygenated and chlorinated 
daphnane diterpenoid orthoester, that had been isolated from the bark of Trigonostemon 
cherrieri Veillon (Euphorbiaceae), a tree collected in the sclerophyllous forest of New-
Caledonia. This genus comprises about 80 species occurring in tropical Asia, from India and Sri 
Lanka to New Guinea.132 These diterpenoids have been shown to have cytotoxic133,134 and 
antiviral135,136 properties. Recently, this natural product was tested against CHIKV and was 
found to inhibit virus-induced cell death in a virus-cell-based assay with an EC50 of 1.5 μM and 
only caused significant anti-metabolic effects at a concentration (CC50) of 35 μM. The 
selectivity index (SI) value was 24. Different concentrations of 16 were able to protect the host 
cells from the virus cytopathic effect without any adverse side-effects. It was also found to be 
more potent than the reference compound used in this study (8).137,138  The assay protocol 
suggests that this compound might inhibit the viral replicase functions, however, for the drug 
discovery process, both the in vivo activity, the precise mode of action as well as the total 
synthesis of this lead compound should be investigated.  
III.8. Trigowiin A, Prostratin and 12‑O‑Tetradecanoylphorbol 13-Acetate. In late 2012, , 
an extract from the bark of Trigonostemon howii from the Euphorbiaceae species out of central 
Vietnam was tested against the CHIKV.139 A new tigliane diterpenoid, trigowiin A (17, Figure 
22) was isolated and was found to be structurally closely related to the tigliane diterpenes 
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(Figure 22), prostratin (a promising adjuvant for anti-HIV therapy)140 (18) and 12-O-
tetradecanoylphorbol 13-acetate (19).139 
 
Figure 22. Chemical structures of 17, 18 and 19. 
 
In a CHIKV assay, 17 showed weak antiviral activity, with an EC50 of 43.5 ± 12.8 μM 
whereas 19 and 18 proved to be the most potent inhibitors, with low EC50 values and higher 
selectivity indices (SI), for 19, EC50 = 0.0029 ± 0.0003 μM and SI = 1965 while the EC50 for 18 
was 2.6 ± 1.5 μM and SI = 30.3 showing that 19 was 65 times more potent than 18.139 At the 
same time, these compounds did not show activity against the Sindbis virus (SINV) nor the 
Semliki forest virus (SFV) which indicates an excellent selectivity for inhibition of the CHIKV. 
The authors139 believe that this selectivity for 19 might be due to a specific mechanism of virus 
inhibition through the activation of the signal transduction enzyme protein kinase C (PKC), 
similar to the proposed mechanism of HIV replication inhibition.141 However, 19 currently is 
one of the most potent tumor-promoting agents known to date,142 therefore, the less potent 18 is 
more likely to be further investigated as a potential candidate, especially as it is shown not to be 
a tumor-promoting agent. The exact mode of action of these compounds is currently unknown 
and needs further investigation. 
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III.9. Lupenone and β-amyrone. In the continuous effort to identify novel inhibitors of 
Chikungunya from natural sources, a phytochemical study on the leaves of Anacolosa 
pervilleana (Madagascan plant) was performed in a virus-cell-based assay for CHIKV.144 The 
triterpenoids isolated showed moderate anti-CHIKV activity (Figure 23) (lupenone (20) EC50 = 
77 μM and β-amyrone (21) EC50 value of 86 μM).
144 Due to their weak activity, these natural 














EC50 = 77 M EC50 = 86 M  
Figure 23. Chemical structures of 20 and 21.  
 
III.10. Harringtonine. Harringtonine (22, Figure 24) is an alkaloid from Cephalotaxus 
harringtonia trees, which is native to Japan and it has a known antitumor activity. It is known to 
inhibit the first cycle of the elongation phase of eukaryotic translation.145 It was shown 
recently146 that 22 displayed potent inhibition of CHIKV infection (EC50 = 0.24 μM) with 
minimal cytotoxicity, through the inhibition of the early stages of infection after cellular 
endocytosis. Also, it was found to affect the CHIKV RNA production inside the infected cell, as 
well as viral protein expression such as the nsP3 and the E2 proteins.146 The in vivo studies of 22 
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EC50 = 0.24 M  
Figure 24. Chemical structure of the alkaloid 22. 
 
III.11. Purine based inhibitors. In 2012, D’hooghe et al. reported the design and synthesis of a 
new series of purine-β-lactam hybrids and purine-aminopropanol hybrids and their evaluation as 
potential antiviral candidates depending on the antiviral templates purines and β-lactams.147 
These new scaffolds were screened against nine different viruses including the chikungunya 
virus. Two purine-β-lactam hybrids and one purine-aminopropanol hybrid (Figure 25) were 
found to possess promising activity and cytotoxicity profiles, the purine-β-lactam (23) with EC50 
= 17.11 μM and SI > 5.75, the purine-β-lactam (24) with EC50 = 13.01 μM and SI > 4 and the 
purine-aminopropanol (25) with EC50 = 11.51 μM and SI > 6.
147 The mode of action has not 
been investigated. The synthesis of this class of compounds is already established and therefore, 




Figure 25. Chemical structures of 23, 24 and 25. 
 
III.12. Polyinosinic acid. Polycytidylic acid [Poly (I:C)] (26, Figure 26), a synthetic double-
stranded RNA (dsRNA) analogue, is an immunostimulant acting as an inducer for the most 
potent interferon (IFN) via interaction with the toll-like receptor 3 (TLR3).148 It can induce IFN-
α/β production and natural killer (NK) cells activation in vivo after intraperitoneal injection.149 
Activation of the TLR3 contributes to an innate immune response against many viruses.150 In 
CHIKV infection, the virus was found to be sensitive to the innate immune response induced by 
26. This sensitivity was noticed as a decreased cytopathic effect and inhibition of the virus 
replication in the infected cell lines. This sensitivity has been explained to be a result of the 




Figure 26. The structure of the dsRNA analogue 26. 
III.13. Gene silencers. New trends in the CHIKV treatment trials are the use of genes silencers 
targeting specific viral proteins (capsid protein, E1, nsP1 and nsP3). Silencing the target viral 
genes will consequently lead to the shutdown of the protein expression process, and thereby 
stopping viral replication. After viral infection, the exogenous small interfering RNA (siRNA) 
induces RNA interference mechanism, resulting in the assembly of the RNA-induced silencing 
complex (RISC) which inhibits subsequent protein expression. Using the siRNA targeting 
CHIKV E1 and nsP3 effectively suppressed in vitro CHIKV replication.152 Similarly, a plasmid 
based small hairpin RNA (shRNA) against CHIKV replication targeting the capsid, E1 and nsP1 
proteins has been used. Simply, the plasmid is introduced to cell and expressed inside the 
nucleus, resulting in the formation of small-hairpin RNA (shRNA) which are processed by the 
cytoplasmic Dicer enzyme to siRNAs, leading to activation of the RNA silencing machinery. 
This silencing machinery recognizes and degrades the target CHIKV single strand RNA, 
consequently stopping viral protein expression.153  Clinical studies should be able to prove the 
applicability of these trends in developing effective anti-CHIKV therapeutics. 
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III.14. Envelope protein antagonists. Targeting the CHIKV envelope proteins,105 possible in 
silico antagonists have been reported based on predicted binding sites. Compounds 27-30 
(Figure 27) were projected to interact with the CHIKV envelope residues critical for the fusion 
process. The (S)-stereochemistry of the OH group in 28-30 was found to be important for the in 
silico binding.105 The antiviral activity for these compounds is yet to be evaluated. 
 
Figure 27. The identified in silico antagonists for the CHIKV envelope proteins. 
 
IV. HIGHLIGHTS FOR CHIKV INHIBITORS 
Several molecules have been tested against the emerging CHIKV with weak to moderate 
activities. Those included drugs already in the market, being used for other diseases, such as 8, 
10, 12 and 15. The challenge here is evolving these structures onto more novel molecules with 
improved potency and maintaining any drug-like qualities. The putative protease inhibitors (5, 
6) and the predicted fusion inhibitors (27-30) developed would be attractive candidates for 
further investigation, however, the challenge lies in being able to identify specific enzyme assay 
protocols to confirm the selectivity for the specific viral proteins. Protein crystallization with the 
inhibitor would be a useful element to validate such studies. Some of the tested compounds 
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represent complex natural products and have sufficient activity as antiviral agents, such as 16, 
18, 19 and 22. It will be a significant task to chemically access these structures and to simplify 
the chemical skeletons to more drug like molecules with acceptable ADME properties. 
The anti-CHIKV activity of the tested molecules ranged from strong to weak inhibition 
depending on the type of the assay used, with the 19 being the strongest inhibitor with EC50 = 
0.0029 μM and 20 which displayed the weakest activity with EC50 = 86 μM, similar activity to 
that of 10, EC50 = 83.3 μM. It is worth noting that the active agents, 19 and the less active 16, 
shared a common structural feature, the substituted benzo[e]azulene derived structure, (Figure 
27). The structure of 19 is simpler than that of 16, lacking the extra phenyl rings, two chlorine 
atoms, four oxygen bridges and the alkene side chain (Figure 27), however, 19 has a 
characteristic long tetradecanoic ester moiety which was responsible for the activity over 17 and 
18, two derivatives that were even less active than 16.  
 
Figure 27. Chemical structures of 19 and 16. The common skeleton is highlighted in bold red 
colour, and groups unique to 19 are shown in green while the excess groups of 16 are shown in 
blue colour. 
V. CONCLUDING REMARKS 
44 
 
Chikungunya virus (CHIKV) is an emerging arbovirus that has had devastating effects in recent 
years in wide ranging areas around the world. Chikungunya virus infection can develop into an 
arthritis disease that remains with the patient for years. The mutations in the viral envelope 
protein genes increased the fitness of the virus in another mosquito vector, Ae. albopictus which 
was responsible for cases reported in temperate zones. With no licensed vaccine for 
immunization against this virus, disease control is currently non-existent, and the defence line 
would be through the development of chemotherapeutics. Some promising lead compounds have 
been discovered recently and could be starting points towards effective treatments. The 
discovery of these leads was mostly based on random screening of drugs already in the market, 
newly discovered natural products or the antiviral evaluation of synthetic compounds. Also, in 
the last two years, the molecular function as well as the crystal structures of a number of critical 
enzymes involved in the virus life cycle have been reported, with no known specific inhibitors 
thus far. Some in silico screens against these proteins have been performed, and while 
compounds with antiviral activity have been identified, their mechanism has yet to be 
confirmed. Substantial medicinal chemistry efforts will be required to advance drug discovery 
and development in this area. Further, despite the availability of whole cell anti-CHIKV testing, 
the development of individual CHIKV enzyme assays would greatly benefit SAR research 
programs as well as helping to identify targets for newly discovered inhibitors. Considering the 
neglected status of this virus and the emerging knowledge of the biology of CHIKV, the 
opportunity for small molecule inhibitors to be discovered and developed remains high. 
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